Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $7.19 million. The enterprise value is $6.22 million.
Important Dates
The last earnings date was Friday, March 21, 2025, before market open.
Earnings Date | Mar 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 8.87 million shares outstanding. The number of shares has increased by 256.75% in one year.
Current Share Class | 8.87M |
Shares Outstanding | 8.87M |
Shares Change (YoY) | +256.75% |
Shares Change (QoQ) | +31.04% |
Owned by Insiders (%) | 13.60% |
Owned by Institutions (%) | 22.98% |
Float | 6.22M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.12 |
Forward PS | 0.15 |
PB Ratio | 1.63 |
P/TBV Ratio | 1.64 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 0.17 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 1.11.
Current Ratio | 1.72 |
Quick Ratio | 0.93 |
Debt / Equity | 1.11 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -8.17 |
Financial Efficiency
Return on equity (ROE) is -384.98% and return on invested capital (ROIC) is -110.06%.
Return on Equity (ROE) | -384.98% |
Return on Assets (ROA) | -43.00% |
Return on Invested Capital (ROIC) | -110.06% |
Return on Capital Employed (ROCE) | -170.73% |
Revenue Per Employee | $439,071 |
Profits Per Employee | -$208,929 |
Employee Count | 93 |
Asset Turnover | 1.49 |
Inventory Turnover | 2.12 |
Taxes
In the past 12 months, Biofrontera has paid $22,000 in taxes.
Income Tax | 22,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.30% in the last 52 weeks. The beta is 0.31, so Biofrontera's price volatility has been lower than the market average.
Beta (5Y) | 0.31 |
52-Week Price Change | -29.30% |
50-Day Moving Average | 1.02 |
200-Day Moving Average | 1.04 |
Relative Strength Index (RSI) | 35.82 |
Average Volume (20 Days) | 94,923 |
Short Selling Information
The latest short interest is 97,753, so 1.10% of the outstanding shares have been sold short.
Short Interest | 97,753 |
Short Previous Month | 81,720 |
Short % of Shares Out | 1.10% |
Short % of Float | 1.57% |
Short Ratio (days to cover) | 1.34 |
Income Statement
In the last 12 months, Biofrontera had revenue of $37.32 million and -$17.76 million in losses. Loss per share was -$3.22.
Revenue | 37.32M |
Gross Profit | 18.71M |
Operating Income | -17.21M |
Pretax Income | -23.08M |
Net Income | -17.76M |
EBITDA | -16.79M |
EBIT | -17.21M |
Loss Per Share | -$3.22 |
Full Income Statement Balance Sheet
The company has $5.91 million in cash and $4.92 million in debt, giving a net cash position of $990,000 or $0.11 per share.
Cash & Cash Equivalents | 5.91M |
Total Debt | 4.92M |
Net Cash | 990,000 |
Net Cash Per Share | $0.11 |
Equity (Book Value) | 4.43M |
Book Value Per Share | 0.50 |
Working Capital | 8.68M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$10.27 million and capital expenditures -$10,000, giving a free cash flow of -$10.28 million.
Operating Cash Flow | -10.27M |
Capital Expenditures | -10,000 |
Free Cash Flow | -10.28M |
FCF Per Share | -$1.16 |
Full Cash Flow Statement Margins
Gross margin is 50.14%, with operating and profit margins of -46.11% and -47.58%.
Gross Margin | 50.14% |
Operating Margin | -46.11% |
Pretax Margin | -47.53% |
Profit Margin | -47.58% |
EBITDA Margin | -44.99% |
EBIT Margin | -46.11% |
FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -256.75% |
Shareholder Yield | -256.75% |
Earnings Yield | -246.16% |
FCF Yield | -142.49% |
Analyst Forecast
The average price target for Biofrontera is $7.00, which is 764.20% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $7.00 |
Price Target Difference | 764.20% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | 25.32% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 0.05:1.
Last Split Date | Jul 5, 2023 |
Split Type | Reverse |
Split Ratio | 0.05:1 |
Scores
Biofrontera has an Altman Z-Score of -7.65 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -7.65 |
Piotroski F-Score | 4 |